These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 19647979)

  • 1. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 2. The science and art of prostate cancer screening.
    Yao SL; Lu-Yao GL
    J Natl Cancer Inst; 2011 Mar; 103(6):450-1. PubMed ID: 21350220
    [No Abstract]   [Full Text] [Related]  

  • 3. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.
    Brenner H; Heywang-Köbrunner S; Becker N
    J Natl Cancer Inst; 2010 Mar; 102(5):356; author reply 356-7. PubMed ID: 20075365
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
    Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
    J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
    Boyle P
    Ann Oncol; 1998 Dec; 9(12):1263-4. PubMed ID: 9932152
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 8. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer screening: and yet it moves!
    Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
    Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 11. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 13. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 15. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 18. Lung cancer screening gets risk-specific.
    Peres J
    J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-cancer screening.
    Preston SH
    N Engl J Med; 2009 Jul; 361(2):202-3; author reply 204-6. PubMed ID: 19593850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.